Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x. x x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 97/2012 Xx. x. x. o Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 12. listopadu 2012 xxxx generální ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx1).
X novým xxxxxx Přílohy I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x platnost x xxxxxxx x xxxxxxx 34 odst. 3 Xxxxxx xxx 1. xxxxx 2013 x tímto xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx platné xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 v Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX XXXXXXXXXX LÁTEK X METOD XXXXXXX XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ KODEX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Specifické xxxxx" kromě xxxxx xx xxxxxx S1, X2, S4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X METODY XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX SOUTĚŽ)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, pokud xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx pouze na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx xxxxxxx této xxxxx: * "exogenní" xx vztahuje k xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx může xxxx xxxxxxxxxx přirozeně.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx jsou xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), stejně xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxx xxxxxxxxxx optických xxxxxxx (např. x- x x-), jsou xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx jsou podány x inhalaci x xxxxxxx s xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 40 ng/ml xxxxxx xxxxxxxxxx za xxxxxxxxx terapeutické xxxxxxx, xxx xxxx považována xx pozitivní xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx pouze na xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx na xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
5. Metabolické xxxxxxxxxx:
x) Xxxxxxxx;
b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) xxxxxxxx/ (xxxx. XX 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x součinnosti x XXXX delta /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (např. XXXXX)
S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx felypressinu xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx použití (Xxx Soutěži, xxxxxxxx Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx spojení s xxxxxxxxxx nebo jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x té, xxxxx xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx maskovací látku.
ZAKÁZANÉ XXXXXX
M1. MANIPULACE X XXXX X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx podobných produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx produkty (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx ne x xxxxxxxx xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx zakázána není.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace s xxxx nebo s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, nebo pokus x xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx ně.
2. Nitrožilní infuze x/xxxx injekce xxxx xxx 50 ml xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx legitimně přijatých x průběhu xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx metod.
X3. XXXXXX DOPING
X xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx zakázáno xxxxxxxxxxx:
1. Transfer xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk;
|
XXXXX X METODY XXXXXXXX XXX SOUTĚŽI
|
Xxxxx xxxxxxxxx X0 xx S5 x X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna stimulancia xxxxxx všech jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- a x-) xxxx zakázaná, x výjimkou xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Monitorovacího programu xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), furfenorex, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (d-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, mezokarb, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
** Xxxxxxx xxxxxx xxxxxxxxxx (např. nosní, xxxx aplikace) xxxx xxxx podání xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx v 1 ml xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx v xxxx xx xxxxx xxx 150 mikrogramů xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, petidin.
S8. XXXXXXXXXXX
Xxxxxxxx (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, JWH073/ x XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX SPORTECH
|
X1. ALKOHOL
Xxxxxxx (xxxxxx) je xxxxxxxx xxxxx Při Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx se xxxx xxxxxxxx dechovou xxxxxxxx a/nebo rozborem xxxx. Prahová hodnota xxx porušeni dopingového xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x parašutismus(FAI)
∙ Lukostřelba (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (FITA, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx a xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx U-rampa x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, propranolol, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
Informace
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. nabyl xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx derogační změna xxxxx xxxxxxxxx právního xxxxxxxx.